This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thery, C. Articles by Coquart, J. P. Search for Related Content PubMed PubMed Citation Articles by Thery, C. Articles by Coquart, J. P.

Circulation, Vol 85, 1380-1389, Copyright © 1992 by American Heart Association

ARTICLES

Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study

C Thery, G Simonneau, G Meyer, O Helenon, F Bridey, C Armagnac, P d'Azemar and JP Coquart
Hopital Cardiologique, Lille, France.

BACKGROUND. We compared the efficacy and safety of different dosages of a low-molecular-weight heparin, CY 216 D (Fraxiparine), in the treatment of submassive pulmonary embolism with unfractionated heparin in a prospective, randomized, dose-finding study. METHODS AND RESULTS. The primary outcome was the evolution of pulmonary vascular obstruction. We enrolled 101 patients. Four patient groups were formed: standard heparin by continuous intravenous infusion (group 1) and Fraxiparine subcutaneously 400, 600, and 900 anti-Xa Institute Choay units/kg, respectively (groups 2, 3, and 4). Inclusions were stopped prematurely in groups 3 and 4 because of the incidence of major bleedings. At day 8, the improvement of the pulmonary vascular obstruction and the major bleedings were similar in groups 1 and 2. CONCLUSIONS. The Fraxiparine dosage of 400 anti-Xa Institute Choay units/kg is as effective and safe as unfractionated heparin in the treatment of submassive pulmonary embolism.

This article has been cited by other articles:

				Authors/Task Force Members, A. Torbicki, A. Perrier, S. Konstantinides, G. Agnelli, N. Galie, P. Pruszczyk, F. Bengel, A. J.B. Brady, D. Ferreira, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur. Heart J., September 2, 2008; 29(18): 2276 - 2315. [Full Text] [PDF]

				C. Kearon, S. R. Kahn, G. Agnelli, S. Goldhaber, G. E. Raskob, and A. J. Comerota Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 454S - 545S. [Abstract] [Full Text] [PDF]

				T. A. Morris, S. Castrejon, G. Devendra, and A. C. Gamst No Difference in Risk for Thrombocytopenia During Treatment of Pulmonary Embolism and Deep Venous Thrombosis With Either Low-Molecular-Weight Heparin or Unfractionated Heparin: A Metaanalysis Chest, October 1, 2007; 132(4): 1131 - 1139. [Abstract] [Full Text] [PDF]

				D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]

				D. J. Quinlan, A. McQuillan, and J. W. Eikelboom Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism: A Meta-Analysis of Randomized, Controlled Trials Ann Intern Med, February 3, 2004; 140(3): 175 - 183. [Abstract] [Full Text] [PDF]

				J. E. Dalen Pulmonary Embolism: What Have We Learned Since Virchow?: Treatment and Prevention Chest, November 1, 2002; 122(5): 1801 - 1817. [Full Text] [PDF]

				M. Riedel VENOUS THROMBOEMBOLIC DISEASE: Acute pulmonary embolism 2: treatment Heart, March 1, 2001; 85(3): 351 - 360. [Full Text]

				M. Meignan, J. Rosso, H. Gauthier, F. Brunengo, S. Claudel, L. Sagnard, P. d'Azemar, G. Simonneau, and B. Charbonnier Systematic Lung Scans Reveal a High Frequency of Silent Pulmonary Embolism in Patients With Proximal Deep Venous Thrombosis Arch Intern Med, January 24, 2000; 160(2): 159 - 164. [Abstract] [Full Text] [PDF]

				P. S C Wong, S. P Singh, R. D S Watson, and G. Y H Lip Management of pulmonary thrombo-embolism using catheter manipulation: a report of four cases and review of the literature Postgrad. Med. J., December 1, 1999; 75(890): 737 - 742. [Abstract] [Full Text]

				M. K. Gould, A. D. Dembitzer, R. L. Doyle, T. J. Hastie, and A. M. Garber Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Meta-Analysis of Randomized, Controlled Trials Ann Intern Med, May 18, 1999; 130(10): 800 - 809. [Abstract] [Full Text] [PDF]

				H. Bounameaux Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism Vascular Medicine, February 1, 1998; 3(1): 41 - 46. [Abstract] [PDF]

				G. Simonneau, H. Sors, B. Charbonnier, Y. Page, J.-P. Laaban, R. Azarian, M. Laurent, J.-L. Hirsch, E. Ferrari, J.-L. Bosson, et al. A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary Embolism N. Engl. J. Med., September 4, 1997; 337(10): 663 - 669. [Abstract] [Full Text] [PDF]

				E. E. Weinmann and E. W. Salzman Deep-Vein Thrombosis N. Engl. J. Med., December 15, 1994; 331(24): 1630 - 1641. [Full Text]

				LOW-MOLECULAR-WEIGHT HEPARIN FOR THROMBOSIS Journal Watch (General), April 21, 1992; 1992(421): 1 - 1. [Full Text]